Empirical assessment of the impact of drug-eluting stents on the rate of use of coronary revascularization procedures

International Journal of Technology Assessment in Health Care

Volumn 20, Issue 3, 2004, Pages 356-360

  Grilli, Roberto ^a   Taroni, Francesco ^a  

^a Agenzia Sanit Regionale Emilia R   (Italy)

Author keywords

Coronary artery bypass; Drug eluting stents; Patterns of care; Percutaneous coronary interventions; Time series analysis

Indexed keywords

CARDIOLOGY; DISEASE CONTROL; DRUG PRODUCTS; STATISTICAL METHODS; SURGERY;

DRUG ELUTING STENTS; PERCUTANEOUS CORONARY INTERVENTIONS (PCI); REVASCULARIZATION PROCEDURES;

HEALTH CARE;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HEART MUSCLE REVASCULARIZATION; HUMAN; ITALY; PERCUTANEOUS CORONARY INTERVENTION; REGRESSION ANALYSIS; TIME SERIES ANALYSIS;

EID: 4043106156     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462304001187     Document Type: Article

References (14)

1. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: I. Circulation. 2002;106:2734-2740.
2. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: II. Circulation. 2002;106:2859-2866.
3. Cook TD, Campbell DT. Quasi-experimentation: Design and analysis issues for field settings. Boston: Houghton Mifflin Company; 1979.
4. Draper N, Smith H. Applied regression analysis. New York: Wiley; 1981.
5. Ferreira AC, Peter AA, Salerno TA, Bolooki H, de Marchena E. Clinical impact of drug-eluting stents in changing referral practices for coronary surgical revascularization in a tertiary care center. Ann Thorac Surg. 2003;75:485-489.
6. Filardo G, Maggioni AP, Mura G, et al. The consequences of under-use of coronary revascularization. Results of a cohort study in Northern Italy. Eur Heart J. 2001;22:654-662.
7. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med. 2002;137:511-520.
8. Marx SO, Marks AR. The development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852-855.
9. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
10. O'Neil D, Miles A, Polychronis A. Central dimensions of clinical practice evaluation: Efficiency, appropriateness and effectiveness. I. J Eval Clin Pract. 1996;2:13-27.
11. Powell AE, Davies HTO, Thomson RG. Using routine comparative data to assess the quality of health care: Understanding and avoiding common pitfalls. Qual Saf Health Care. 2003;12:122-128.
12. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series design in implementation research: Lessons from two systematic reviews of behavior change strategies. Int J Technol Assess Health Care. 2003;19:613-623.
13. Rensing BJ, Vos J, Smits PC, et al. Coronary restenosis elimination with a sirolimus eluting stent. Eur Heart J. 2001;22:2125-2130.
14. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents. One-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-2011.